Janet Ayello

Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation.

Charles Hesdorffer, Janet Ayello, Maureen Ward et al. · Journal of Clinical Oncology · 1998 · 217 citations

Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells <i>In Vitro</i> and in NSG Mice

Yaya Chu, Jessica Hochberg, Ashlin Yahr et al. · Cancer Immunology Research · 2014 · 168 citations · Full text

Expbnk-treated Mice, Immunology, Immune Regulation +17

Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia

Aradhana Awasthi, Janet Ayello, Carmella van de Ven et al. · British Journal of Haematology · 2015 · 89 citations · Full text

Obinutuzumab Versus Rituximab, Immunology, Cell Death +16

Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma <i>in vitro</i> and in immunodeficient mice

Yaya Chu, Ashlin Yahr, Brian Z. Huang et al. · OncoImmunology · 2017 · 78 citations · Full text

Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report

Stacey L. Berg, Mitchell S. Cairo, Heidi V. Russell et al. · Journal of Clinical Oncology · 2010 · 59 citations · Full text